Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan-Mar;14(1):14-22.
doi: 10.14797/mdcj-14-1-14.

Stenting in Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Affiliations
Review

Stenting in Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Sanjog Kalra et al. Methodist Debakey Cardiovasc J. 2018 Jan-Mar.

Abstract

The treatment of ST-segment elevation myocardial infarction (STEMI) has advanced dramatically over the past 30 years since the introduction of reperfusion therapies, such that mechanical reperfusion with primary percutaneous coronary intervention is now the standard of care. With STEMI, as with other forms of acute coronary syndrome, stent deployment in culprit lesions is the dominant form of reperfusion in the developed world and is supported by contemporary guidelines. However, the precise timing of stenting and the extent to which both culprit and non-culprit lesions should be treated continue to be active areas of study. In this review, we revisit key data that support the use of mechanical reperfusion therapy in STEMI patients and explore the optimal timing for and extent of stent implantation in this complex patient group. We also review data surrounding the deleterious effects of untreated residual myocardial ischemia, the importance of complete revascularization, and the recent data exploring culprit-only versus multivessel stenting in the STEMI setting.

Keywords: PCI; STEMI; acute coronary syndrome; mechanical reperfusion; stenting.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: Dr. Kirtane conducts research (via institutional grants to Columbia University/CRF) on behalf of Medtronic, Abbott Vascular, Boston Scientific, Abiomed, Cath Works, Siemens, Philips, ReCor Medical, and Spectranetics. Dr. Kalra is a speakers' bureau member for Abiomed and ACIST Medical Systems.

Figures

Figure 1.
Figure 1.
Coronary no-reflow phenomenon. (A) Coronary capillary network after myocardial reperfusion, and (B) pathological comparison between reflow and no-reflow. Reprinted with permission.
Figure 2.
Figure 2.
Schematic representation of treatment strategies for significant non-culprit coronary lesions following primary PCI for STEMI. Treatment strategies include medical therapy and/or partial or complete revascularization performed during index hospitalization or as a staged procedure. Reprinted with permission. PCI: percutaneous intervention; STEMI: ST-elevated myocardial infarction; FFR: fractional flow reserve

References

    1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986. February 22; 1 8478: 397– 402. - PubMed
    1. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988. August 13; 2 8607: 349– 60. - PubMed
    1. [GUSTO (Global Utilization of Streptokinase & t-PA for Occluded Coronary Arteries): comparison of four therapeutic strategies in acute myocardial infarction. Washington, 30 April 1993]. Internist (Berl). 1993. July; 34 7 Suppl: 1– 12. - PubMed
    1. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet. 1995. August 5; 346 8971: 329– 36. - PubMed
    1. Van De Werf F, Adgey J, Ardissino D, . et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999. August 28; 354 9180: 716– 22. - PubMed

MeSH terms

LinkOut - more resources